Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
IPXL's Cash to Debt is ranked higher than
98% of the 926 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. IPXL: No Debt )
IPXL' s 10-Year Cash to Debt Range
Min: 0.73   Max: No Debt
Current: No Debt

Equity to Asset 0.82
IPXL's Equity to Asset is ranked higher than
88% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. IPXL: 0.82 )
IPXL' s 10-Year Equity to Asset Range
Min: 0.12   Max: 0.82
Current: 0.82

0.12
0.82
Interest Coverage 2065.49
IPXL's Interest Coverage is ranked higher than
74% of the 566 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.63 vs. IPXL: 2065.49 )
IPXL' s 10-Year Interest Coverage Range
Min: 0.82   Max: 9999.99
Current: 2065.49

0.82
9999.99
F-Score: 6
Z-Score: 11.17
M-Score: -2.24
WACC vs ROIC
14.11%
12.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 14.90
IPXL's Operating margin (%) is ranked higher than
85% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.10 vs. IPXL: 14.90 )
IPXL' s 10-Year Operating margin (%) Range
Min: -1418.74   Max: 44.72
Current: 14.9

-1418.74
44.72
Net-margin (%) 9.62
IPXL's Net-margin (%) is ranked higher than
80% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.05 vs. IPXL: 9.62 )
IPXL' s 10-Year Net-margin (%) Range
Min: -1376.35   Max: 46
Current: 9.62

-1376.35
46
ROE (%) 6.70
IPXL's ROE (%) is ranked higher than
75% of the 895 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. IPXL: 6.70 )
IPXL' s 10-Year ROE (%) Range
Min: -341.31   Max: 125.75
Current: 6.7

-341.31
125.75
ROA (%) 5.51
IPXL's ROA (%) is ranked higher than
81% of the 930 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.82 vs. IPXL: 5.51 )
IPXL' s 10-Year ROA (%) Range
Min: -70.9   Max: 38.8
Current: 5.51

-70.9
38.8
ROC (Joel Greenblatt) (%) 27.32
IPXL's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.02 vs. IPXL: 27.32 )
IPXL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -297.18   Max: 235.82
Current: 27.32

-297.18
235.82
Revenue Growth (3Y)(%) 3.50
IPXL's Revenue Growth (3Y)(%) is ranked higher than
69% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. IPXL: 3.50 )
IPXL' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 203.4
Current: 3.5

0
203.4
EBITDA Growth (3Y)(%) 1.60
IPXL's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. IPXL: 1.60 )
IPXL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 61.6
Current: 1.6

0
61.6
EPS Growth (3Y)(%) -5.80
IPXL's EPS Growth (3Y)(%) is ranked higher than
67% of the 667 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.10 vs. IPXL: -5.80 )
IPXL' s 10-Year EPS Growth (3Y)(%) Range
Min: -32.2   Max: 55.1
Current: -5.8

-32.2
55.1
» IPXL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

IPXL Guru Trades in Q1 2014

John Hussman 220,000 sh (New)
Steven Cohen 63,998 sh (+266.25%)
Paul Tudor Jones 18,000 sh (+62.16%)
Jim Simons 1,046,000 sh (-25.73%)
RS Investment Management 1,328,437 sh (-43.48%)
» More
Q2 2014

IPXL Guru Trades in Q2 2014

NWQ Managers 984,841 sh (New)
John Hussman 310,000 sh (+40.91%)
Paul Tudor Jones 18,000 sh (unchged)
Jim Simons Sold Out
RS Investment Management 940,950 sh (-29.17%)
» More
Q3 2014

IPXL Guru Trades in Q3 2014

Joel Greenblatt 33,709 sh (New)
Jim Simons 39,400 sh (New)
Paul Tudor Jones 36,853 sh (+104.74%)
NWQ Managers 1,298,995 sh (+31.9%)
RS Investment Management 809,959 sh (-13.92%)
John Hussman 250,000 sh (-19.35%)
» More
Q4 2014

IPXL Guru Trades in Q4 2014

Mario Gabelli 6,775 sh (New)
Alan Fournier 533,100 sh (New)
Joel Greenblatt 79,609 sh (+136.17%)
Jim Simons 61,400 sh (+55.84%)
Paul Tudor Jones 39,050 sh (+5.96%)
John Hussman 250,000 sh (unchged)
RS Investment Management Sold Out
NWQ Managers 906,043 sh (-30.25%)
» More
» Details

Insider Trades

Latest Guru Trades with IPXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
NWQ Managers 2014-12-31 Reduce -30.25%0.1%$23.63 - $32.75 $ 40.2938%906043
Joel Greenblatt 2014-12-31 Add 136.17%0.01%$23.63 - $32.75 $ 40.2937%79609
Mario Gabelli 2014-12-31 New Buy$23.63 - $32.75 $ 40.2938%6775
John Hussman 2014-09-30 Reduce -19.35%0.14%$22.77 - $30.68 $ 40.2958%250000
NWQ Managers 2014-09-30 Add 31.9%0.08%$22.77 - $30.68 $ 40.2958%1298995
Joel Greenblatt 2014-09-30 New Buy0.01%$22.77 - $30.68 $ 40.2958%33709
NWQ Managers 2014-06-30 New Buy0.3%$23.6 - $30.68 $ 40.2950%984841
John Hussman 2014-06-30 Add 40.91%0.21%$23.6 - $30.68 $ 40.2950%310000
John Hussman 2014-03-31 New Buy0.44%$22.02 - $27.91 $ 40.2962%220000
John Hussman 2012-03-31 Sold Out 0.11%$18.64 - $24.37 $ 40.2994%0
Joel Greenblatt 2012-03-31 Sold Out 0.05%$18.64 - $24.37 $ 40.2994%0
Joel Greenblatt 2011-12-31 Reduce -88.51%0.47%$16.53 - $20.75 $ 40.29116%21057
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 49.60
IPXL's P/E(ttm) is ranked higher than
75% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 48.60 vs. IPXL: 49.60 )
IPXL' s 10-Year P/E(ttm) Range
Min: 4.04   Max: 1043
Current: 49.6

4.04
1043
Forward P/E 25.91
IPXL's Forward P/E is ranked higher than
84% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 58.14 vs. IPXL: 25.91 )
N/A
PE(NRI) 49.60
IPXL's PE(NRI) is ranked higher than
75% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 48.50 vs. IPXL: 49.60 )
IPXL' s 10-Year PE(NRI) Range
Min: 4.04   Max: 1043
Current: 49.6

4.04
1043
P/B 3.23
IPXL's P/B is ranked higher than
74% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. IPXL: 3.23 )
IPXL' s 10-Year P/B Range
Min: 1.32   Max: 16.6
Current: 3.23

1.32
16.6
P/S 4.77
IPXL's P/S is ranked higher than
69% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.01 vs. IPXL: 4.77 )
IPXL' s 10-Year P/S Range
Min: 1.15   Max: 16.27
Current: 4.77

1.15
16.27
POCF 85.72
IPXL's POCF is ranked higher than
71% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.53 vs. IPXL: 85.72 )
IPXL' s 10-Year POCF Range
Min: 3.18   Max: 2002
Current: 85.72

3.18
2002
EV-to-EBIT 27.69
IPXL's EV-to-EBIT is ranked higher than
81% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.09 vs. IPXL: 27.69 )
IPXL' s 10-Year EV-to-EBIT Range
Min: -1981.9   Max: 628.6
Current: 27.69

-1981.9
628.6
Shiller P/E 25.30
IPXL's Shiller P/E is ranked higher than
89% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 103.75 vs. IPXL: 25.30 )
IPXL' s 10-Year Shiller P/E Range
Min: 10.16   Max: 61.99
Current: 25.3

10.16
61.99
Current Ratio 4.60
IPXL's Current Ratio is ranked higher than
84% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.36 vs. IPXL: 4.60 )
IPXL' s 10-Year Current Ratio Range
Min: 0.34   Max: 5.64
Current: 4.6

0.34
5.64
Quick Ratio 4.10
IPXL's Quick Ratio is ranked higher than
85% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. IPXL: 4.10 )
IPXL' s 10-Year Quick Ratio Range
Min: 0.34   Max: 5.19
Current: 4.1

0.34
5.19
Days Inventory 102.46
IPXL's Days Inventory is ranked higher than
83% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 153.90 vs. IPXL: 102.46 )
IPXL' s 10-Year Days Inventory Range
Min: 50.25   Max: 398.94
Current: 102.46

50.25
398.94
Days Sales Outstanding 89.71
IPXL's Days Sales Outstanding is ranked higher than
72% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.97 vs. IPXL: 89.71 )
IPXL' s 10-Year Days Sales Outstanding Range
Min: 34.05   Max: 1169.47
Current: 89.71

34.05
1169.47

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.83
IPXL's Price/Net Cash is ranked higher than
92% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. IPXL: 12.83 )
IPXL' s 10-Year Price/Net Cash Range
Min: 7.74   Max: 14.67
Current: 12.83

7.74
14.67
Price/Net Current Asset Value 7.69
IPXL's Price/Net Current Asset Value is ranked higher than
91% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. IPXL: 7.69 )
IPXL' s 10-Year Price/Net Current Asset Value Range
Min: 4.5   Max: 14.67
Current: 7.69

4.5
14.67
Price/Tangible Book 3.44
IPXL's Price/Tangible Book is ranked higher than
78% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.29 vs. IPXL: 3.44 )
IPXL' s 10-Year Price/Tangible Book Range
Min: 1.45   Max: 26.35
Current: 3.44

1.45
26.35
Price/DCF (Projected) 2.93
IPXL's Price/DCF (Projected) is ranked higher than
84% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.24 vs. IPXL: 2.93 )
IPXL' s 10-Year Price/DCF (Projected) Range
Min: 1.41   Max: 3.82
Current: 2.93

1.41
3.82
Price/Median PS Value 1.48
IPXL's Price/Median PS Value is ranked higher than
69% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. IPXL: 1.48 )
IPXL' s 10-Year Price/Median PS Value Range
Min: 0.46   Max: 25.85
Current: 1.48

0.46
25.85
Price/Graham Number 2.77
IPXL's Price/Graham Number is ranked higher than
81% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.07 vs. IPXL: 2.77 )
IPXL' s 10-Year Price/Graham Number Range
Min: 0.79   Max: 2.45
Current: 2.77

0.79
2.45
Earnings Yield (Greenblatt) 3.60
IPXL's Earnings Yield (Greenblatt) is ranked higher than
81% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. IPXL: 3.60 )
IPXL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 55.9
Current: 3.6

0.2
55.9
Forward Rate of Return (Yacktman) -22.09
IPXL's Forward Rate of Return (Yacktman) is ranked higher than
56% of the 527 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.94 vs. IPXL: -22.09 )
IPXL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -22.1   Max: 61
Current: -22.09

-22.1
61

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:ILR.Germany,
Impax Laboratories, Inc., is a Delaware corporation was incorporated in 1995. It is a technology-based, specialty pharmaceutical company applying formulation and development expertise, as well as its drug delivery technology, to the development, manufacture and marketing of bioequivalent pharmaceutical products, commonly referred to as 'generics' in addition to the development and marketing of branded products. The Company operates in two segments namely Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The Global Division develops, manufactures, sells and distributes its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established nonproprietary drug names rather than by a brand name. The Company develops, manufacture, sell and distribute specialty generic pharmaceuticals. The Global Division develops, manufactures, sells, and distributes generic pharmaceutical products mainly through four sales channels: the 'Global products' sales channel, for generic pharmaceutical prescription products the Company sells directly to wholesalers, large retail drug chains, and others; the 'Private Label' sales channel, for generic pharmaceutical over-the-counter ('OTC') and prescription products the Company sells to unrelated third-party customers who in-turn sell the product to third parties under its own label; the 'Rx Partner' sales channel, for generic prescription products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements; and the 'OTC Partner' sales channel, for sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements. The Impax Division is engaged in the development of proprietary brand pharmaceutical products. The Impax Division is also engaged in the sale and distribution of branded Zomig(r) (zolmitriptan) products, indicated for the treatment of migraine headaches, under the terms of a Distribution, License, Development and Supply Agreement (AZ Agreement) with AstraZeneca UK Limited (AstraZeneca). The Company's Impax Division develops proprietary brand pharmaceutical products through improvements to already approved pharmaceutical products to address central nervous system ('CNS') disorders. The Impax Division is also engaged in the co-promotion through a direct sales force focused on marketing to physicians, mainly in the CNS community, pharmaceutical products developed by other unrelated third-party pharmaceutical entities. The Company markets and sells its generic pharmaceutical prescription drug products within the continental United States of America and the Commonwealth of Puerto Rico. The chemical raw materials, essential to its business, are generally readily available from multiple sources in the U.S. and throughout the world. Generic pharmaceutical product deve
» More Articles for IPXL

Headlines

Articles On GuruFocus.com
Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
comment on IPXL Sep 24 2012 
President and CEO of Impax Laboratories Inc. (IPXL) Larry Hsu Bought 10,000 Shares Aug 17 2011 
Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 5,000 Shares Aug 12 2010 
Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 10,000 Shares Aug 12 2010 
Impax Laboratories Reports Second Quarter 2009 Financial Results Aug 04 2009 


More From Other Websites
The oil selloff created this buying opportunity Feb 26 2015
JPM Securities Picks Through Biotech News For Winners Feb 25 2015
Pacira Misses Earnings Estimates in Q4, Revenues In Line - Analyst Blog Feb 25 2015
Impax to Present at the Cowen and Company 35th Annual Health Care Conference Feb 25 2015
Novartis' Farydak Approved for Multiple Myeloma with Warning - Analyst Blog Feb 24 2015
Will Allscripts (MDRX) Surprise Earnings Estimates in Q4? - Analyst Blog Feb 24 2015
Impax Labs tops Street 4Q forecasts Feb 24 2015
Impax Labs tops Street 4Q forecasts Feb 24 2015
IMPAX LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 24 2015
Assembly Biosciences (ASMB) in Focus: Stock Falls 7.4% - Tale of the Tape Feb 24 2015
Q4 2014 Impax Laboratories Inc Earnings Release - Before Market Open Feb 24 2015
Impax Revenues Increased 30% to $131 Million in Fourth Quarter 2014 Feb 24 2015
Will Celldex Therapeutics (CLDX) Disappoint This Earnings? - Analyst Blog Feb 23 2015
Pfizer Rapamune Under FDA Priority Review for Lung Disease - Analyst Blog Feb 23 2015
Will BioMarin (BMRN) Beat Estimates this Earnings Season? - Analyst Blog Feb 23 2015
Will Exelixis (EXEL) Miss Estimates this Earnings Season? - Analyst Blog Feb 23 2015
Will DexCom (DXCM) Loss Better Estimates this Earnings? - Analyst Blog Feb 23 2015
What's in Store for Endocyte (ECYT) this Earnings Season? - Analyst Blog Feb 20 2015
Can Greatbatch (GB) Keep the Earnings Streak Alive in Q4? - Analyst Blog Feb 20 2015
Will Gogo's (GOGO) Earnings Beat Estimates this Season? - Analyst Blog Feb 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK